Zoledronic acid versus pamidronate: Cost minimisation in bone metastasis

Journal of Medical Economics

Volumn 8, Issue 1-12, 2005, Pages 1-12

  Slof, John ^a   Badia, Xavier ^b   Lizán, Luis ^b   Bautista, Francisco J ^c   Echarri, Eduardo ^d   Hurlé, Alfonso D G ^e   Pla, Ramon ^f   Mangues, M Antonia ^g   Rodríguez Sasiaín, José Miguel ^h   Wood, Miguel A ⁱ  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b Health Outcomes Research Europe   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^d HOSPITAL DE CONXO   (Spain)

^e UNIVERSITY OF SALAMANCA   (Spain)

^f HOSPITAL MÚTUA DE TERRASSA   (Spain)

^g HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^h HOSPITAL DE GALDAKAO   (Spain)

ⁱ HOSPITAL UNIVERSITARIO MATERNO INFANTIL DE CANARIAS   (Spain)

Author keywords

Bone metastasis; Cost minimisation; Economic evaluation; Pamidronate; Zoledronic acid

Indexed keywords

PAMIDRONIC ACID; ZOLEDRONIC ACID;

ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST MINIMIZATION ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; DRUG FEVER; DRUG INFUSION; DRUG POTENCY; EUROPE; FATIGUE; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; HYPERCALCEMIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE MYELOMA; NAUSEA; NURSE; PAIN; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 13444256141     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/200508001012     Document Type: Article

References (24)

1. Coleman R. Incidence and distribution of bone metastases. In: Diel IJ, Kaufmann M, Bastert G, Editors. Metastatic bone disease. Heidelberg, Germany: Springer Verlag, 1994: 20-30.
2. Galasko CSB. The anatomy and pathways of skeletal metastases. In: Weiss L, Gilbert AH, Editors. Bone metastases. Boston, MA: Hall, 1981: 49-63.
3. Coleman RE. Management of bone metastases. Oncologist 2000; 5: 463-470.
4. Rogers MJ, Watts DJ, Russell RG. Overview of bisphosphonates. Cancer 1997; 80 (Suppl 8): 1652-1660.
5. Body JJ, Bartl R, Burckhardt P et al. Current use of bisphosphonates in oncology. Journal of Clinical Oncology 1998; 16: 3890-3899.
6. Hillner BE, Ingle JN, Berenson JR et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. Journal of Clinical Oncology 2000; 18: 1378-1391.
7. Berenson JR, Hillner BE, Kyle RA et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in multiple myeloma. Journal of Clinical Oncology 2000; 20: 3719-3736.
8. Body JJ, Mancini I. Bisphosphonates for cancer patients: why, how, and when? Support Care Cancer 2002; 10: 399-407.
9. Green JR, Müller K, Jaeggi KA. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic biophosphonate compound. Journal of Bone and Mineral Research 1994; 9: 745-751.
10. Rosen LS, Gordon D, Kaminsky M et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer Journal 2001; 7: 377-387.
11. Major P, Lortholary A, Hon J et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. Journal of Clinical Oncology 2001; 19: 558-567.
12. DesHarnais Castel L, Bajwa K, Markle JP et al. A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease. Support Care Cancer 2001; 9: 539-544.
13. Ross JR, Saunders Y, Edmonds PM et al. Systematic review of role of bisphosponates on skeletal morbidity in metastatic cancer. British Medical Journal 2003; 327: 469. [Erratum. British Medical Journal 2004; 328: 384.]
14. Ross JR, Saunders Y, Edmonds PM et al. Systematic review of role of bisphosponates on skeletal morbidity in metastatic cancer. British Medical Journal 2003; 327: 469. [Erratum. British Medical Journal 2004; 328: 384.]
15. Berenson J, Hirschberg R. Safety and convenience of a 15-minute infusion of zoledronic acid. The Oncologist 2004; 9: 319-329.
16. Balducci L, Extermann M, Patterson S et al. Cost-effectiveness of pamidronate in the treatment of breast cancer in the metastatic and in the adjuvant setting. Proceedings of the American Society of Clinical Oncology 1998; 17: 415a (Abstr. 1599).
17. Dranitsaris G, Hsu T. Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer. Support Care Cancer 1999; 7: 721-729.
18. Hillner BE, Weeks JC, Desch CE, et al. Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. Journal of Clinical Oncology 2000; 18: 72-79.
19. McCloskey EV, Guest JF, Kanis JA. The clinical and cost considerations of bisphosphonates in preventing bone complications in patients with metastatic breast cancer or multiple myeloma. Drugs 2001; 61: 1253-1274.
20. Parison D, Turcotte L, Dranitsaris G. Cost-utility analysis of pamidronate in patients with multiple myeloma. Support Care Cancer 1998; 6: 183.
21. SOIKOS. Base de datas de castes sanitarios [Healthcare costs database]. Barcelona, Spain: Centro de Estudios en Economía de Salud y Política Social, 2003.
22. Conill C, Bisbe J, Verger E, Borrás JM. Análisis de costes por procedimiento en una Unidad de Oncología Radioterápica [Analysis of procedure costs in an oncological radioterapy unit]. Todo Hospital 1996; 126: 19-28.
23. Coleman RE, Rosen LS, Gordon D et al. Zoledronic acid (4 mg) significantly reduces the relative risk of developing a skeletal-related event compared with pamidronate (90 mg) in patients with breast cancer and bone metastasis (abstract). Presented at 25th Annual San Antonio Breast Cancer Symposium, San Antonio, December 11-14, 2002.
24. Rose MR, Kagan AR. The Final Report of the Expert Panel for the Radiation Onclology Bone Metastasis Work Group of the American College of Radiology. Interntional Journal of Radiation Oncology, Biology, Physics 1998; 40: 1117-1124.